Nura Bio secured a $73.8 million Series B round to advance SARM1 inhibitor programs for neurodegeneration, the company said. The funding is intended to support two clinical-stage efforts through early development, positioning the firm for additional efficacy and safety readouts as it moves toward later-phase trials. The financing highlights continued investor appetite for target-driven neurodegeneration strategies, particularly those addressing axonal degeneration pathways through small-molecule intervention. Nura’s plan to use the proceeds to progress multiple programs also suggests a portfolio approach rather than a single-asset bet. While detailed trial designs weren’t included in the report, the Series B magnitude signals that SARM1 remains an actively pursued mechanism, with capital now enabling study expansion and data generation needed for subsequent regulatory and partnership decisions.